

TABLE OF CONTENTS

Contents	Page No.
Abstract	i-v
Declaration	
Certificate	
Acknowledgements	vi-viii
Table of Contents	ix-xiv
List of Tables	xv-xvii
List of Figures	xviii-xxii
List of Symbols and Abbreviations	xxiii-xxiv

Table of Contents

Contents	Page No.
Chapter I: Introduction	1-36
1.1 Significance and approaches to drug discovery from natural products	1
1.1.1 Bioactivity-guided isolation	4
1.1.2 Metabolic profiling	4
1.2 Significance of medicinal plants in drug discovery	5
1.3 Cardiovascular diseases and cardiovascular drugs from medicinal plant	8
1.3.1 Cardiovascular diseases- A major burden of human life	8
1.3.2 Classification of cardiovascular drugs	10
1.3.2.1 Anticoagulant drugs	11
1.3.2.2 Thrombolytic drugs	13
1.3.2.3 Antiplatelet drugs	13
1.3.3 Cardiovascular drugs from medicinal plants: Special example of Ayurveda	13
1.4 Selection of Indian medicinal plants for the current study	16
1.4.1 Previous pharmacological and phytochemical evaluation of the selected medicinal plants	16
1.5 Rationale of the project	18
1.6 Aims and Objectives of the present study	19
Bibliography	20
Chapter II: Review of Literature	37-67
2.1 Natural products towards the discovery of potential future antithrombotic drugs	37
2.2 Cardiovascular diseases and natural products	37
2.3 Thrombosis and platelet aggregation	39
2.3.1 Coagulation system	40
2.3.2 Platelet activation and aggregation	41
2.3.3 Antithrombotic effects of plant derived natural products	42
2.3.3.1 Anticoagulants derived from medicinal plants	42
2.3.3.2 Inhibition of tissue factors by natural products	42
2.3.3.3 Effect on coagulation pathways by natural products	43
2.4 Platelet aggregation inhibition property of plant-derived natural products	43
2.5 Fibrinolysis by natural products form plants	51
Bibliography	52

Contents	Page No.
Chapter III: Materials and Methods	68-102
3.1 Materials	68
3.1.1 Collection of plant samples	68
3.1.2 Chemicals	68
3.2 Methods	69
3.2.1 Preparation and screening of extracts of ethno-medicinal plants of Assam for anticoagulant activities	69
3.2.2 Identification of selected plant species	70
3.2.3 Optimization of extraction conditions of <i>Leucas indica</i> and <i>Momordica charantia</i>	70
3.2.3.1 Optimization of stirring time of extraction	70
3.2.3.2 Optimization of pH of water	70
3.2.3.3 Optimization of temperature for extraction	71
3.2.3.4 Optimization of sonication time for extraction	71
3.2.4 Preparation of anticoagulant active fraction from <i>L. indica</i>	71
3.2.5 Preparation of active anticoagulant fraction of <i>M. charantia</i>	72
3.2.6 Biophysical characterization	73
3.2.6.1 Purity of preparation and molecular mass determination	73
3.2.6.1.1 SDS-PAGE analysis	73
3.2.6.1.2 MALDI-TOF-MS analysis	75
3.2.6.2 LC-MS/MS analysis	75
3.2.6.3 Determination of secondary structure of protein	76
3.2.6.4 Amino acid compositional analysis	76
3.2.6.5 GC-MS analysis of active fraction	77
3.2.6.6 Interaction studies by spectrofluorometric analysis	77
3.2.6.7 ITC (Isothermal Calorimetry) analysis of thrombin and fibrinogen	78
3.2.6.8 <i>In silico</i> study to determine interaction between active component (BSS) of active fraction of <i>L. indica</i> (AFLI) and thrombin	79
3.2.7 Biochemical characterization	79
3.2.7.1 Qualitative analysis of active fractions	79
3.2.7.1.1 Test for Alkaloids	79
3.2.7.1.2 Test for Flavonoids	80
3.2.7.1.3 Test for phenolic compounds	80
3.2.7.1.4 Test for gum and mucilage	80
3.2.7.1.5 Test for fixed oils and fats	80
3.2.7.1.6 Test for glycoside	80
3.2.7.1.7 Test for steroid	81
3.2.7.1.8 Test for tannins	81
3.2.7.1.9 Test for reducing sugar	81
3.2.7.2 Estimation of protein content	81
3.2.7.3 Casein/plasma protein hydrolysis activity	82
3.2.7.4 Fibrinolytic/fibrinogenolytic activity assay	82
3.2.7.4.1 Colorimetric assay	82
3.2.7.4.2 SDS-PAGE analysis	83
3.2.7.5 RP-HPLC analysis of fibrin(ogen) degradation products	83

Contents	Page No.
3.2.7.6 Determination of kinetic parameters of fibrinolytic activity	83
3.2.7.7 Effect on extracellular matrix (ECM) proteins	84
3.2.7.8 Thrombin inhibition studies	84
3.2.7.8.1 Inhibition of amidolytic activity of thrombin	84
3.2.7.8.2 Determination of inhibitory constant (K_i) for thrombin inhibition	84
3.2.7.8.3 Effect on fibrinogen clotting activity of thrombin	85
3.2.7.8.4 Determination of effect of active component on thrombin inhibition by AT-III in the presence or absence of heparin	86
3.2.7.9 Factor Xa inhibition studies	86
3.2.7.9.1 Effect on the prothrombin activation property of factor Xa	86
3.2.7.9.2 Determination of inhibitory constant (K_i) for factor Xa inhibition	86
3.2.7.10 Determination of plasminogen activating assay	87
3.2.7.11 Biochemical characterizations of active fractions and purified protein	88
3.2.7.11.1 Chemical modification of active site of purified protein	88
3.2.7.11.2 Determination of optimum temperature and pH for enzymatic activity	88
3.2.7.11.3 Stability study	89
3.2.8 Pharmacological characterization	89
3.2.8.1 Plasma re-calcification time	89
3.2.8.2 Prothrombin time test	90
3.2.8.3 Activated partial thromboplastin time test	90
3.2.8.4 Platelet modulating activity	90
3.2.8.5 <i>In vitro</i> hemolytic activity	91
3.2.8.6 <i>In vitro</i> cytotoxicity assay	92
3.2.8.6.1 MTT-based assay	92
3.2.8.6.2 Calcein-AM cell viability staining	93
3.2.8.6.3 Flow cytometry analysis to determine the cell cycle kinetics	93
3.2.8.6.4 Effect on the cytochrome P450 enzyme system	93
3.2.8.7 <i>In vitro</i> clot lysing activity	94
3.2.9 <i>In vivo</i> toxicity assessment	94
3.2.9.1 Assessment of acute <i>in vivo</i> toxicity	95
3.2.9.2 Histopathological studies	96
3.2.10 Determination of <i>in vivo</i> defibrinogenating activity and anticoagulant potency	96
3.2.11 Determination of <i>in vivo</i> antithrombotic activity	97
3.3 Statistical analysis	97
Bibliography	98

Contents	Page No.
Chapter IV: Screening of selected medicinal plants of Assam for assessment of anticoagulant property and preparation of active anticoagulant fraction from selected plants	103-140
4.1 Brief introduction	103
4.2 Results	104
4.2.1 The aqueous extract of the leaves of <i>Leucas indica</i> and <i>Momordica charantia</i> showed superior anticoagulant activity	104
4.2.2 Optimization of extraction conditions of <i>L. indica</i> and <i>M. charantia</i>	104
4.2.3 Preparation of active anticoagulant fraction (AFLI) from aqueous leaves extract of <i>L. indica</i>	106
4.2.4 Gas chromatography–mass spectrometry analysis of AFLI	110
4.2.5 SDS-PAGE analysis of AFLI	110
4.2.6 LC-MS/MS analysis of major protein constituent of AFLI	111
4.2.7 Formulation of active anticoagulant preparation (AAP)	112
4.2.8 Dose- and time-dependent anticoagulant activity of AAP and AFLI	112
4.2.9 Inhibition of catalytic activity of thrombin and FXa by AAP	115
4.2.10 Fibrin(ogen)olytic activity of AAP	118
4.2.11 Spectrofluorometric analysis to determine the interaction of AAP with thrombin/ fibrinogen/ FXa	119
4.2.12 AAP demonstrated <i>in vitro</i> thrombolytic activity	121
4.2.13 AAP is devoid of hemolytic activity and cytotoxicity against mammalian cells and did not affect the cytochrome P450 enzymes	122
4.2.14 AAP showed antiplatelet activity and also inhibited the collagen and ADP-induced platelet aggregation	124
4.2.15 Determination of <i>in vivo</i> toxicity of AAP in Swiss albino mice	125
4.2.16 Effect on haematological and serum biochemical parameters of AAP-treated mice	126
4.2.17 Histopathological study of tissues obtained from AAP-treated and control group of mice	128
4.2.18 AAP demonstrated <i>in vivo</i> anticoagulant and defibrinogenating activity	129
4.2.19 Antithrombotic effect of AAP against k-carrageenan-induced tail thrombus in mice	131
4.3 Discussion	132
Bibliography	136
Chapter V: Characterization and mechanism of anticoagulant action of a fibrin(ogen)olytic serine protease (Lunathrombase) purified from active fraction of <i>L. Indica</i> (AFLI)	141-190
5.1 Brief Introduction	141
5.2 Results	142
5.2.1 Purification of major fibrinogenolytic protease from the leaves of <i>L. indica</i>	142
5.2.2 Peptide mass fingerprinting, de novo sequencing, amino acid composition, and secondary structure analyses of lunathrombase	145
5.2.3 Lunathrombase demonstrated anticoagulant activity	148

Contents	Page No.
5.2.4 Fibrin(ogen)olytic activity of lunathrombase	149
5.2.5 RP-UHPLC analysis of fibrinogen degradation by lunathrombase and nattokinase	152
5.2.6 FPA and FPB did not influenced the fibrinogenolytic activity of lunathrombase	153
5.2.7 Substrate specificity and effect of temperature and pH on catalytic activity of lunathrombase	153
5.2.8 Lunathrombase is devoid of N- or O-linked oligosaccharides	155
5.2.9 Inhibitor study shows lunathrombase is a serine protease and its activity is not influenced by the endogenous protease inhibitors of plasma	155
5.2.10 Lunathrombase inhibits the pharmacological activity of thrombin and FXa-the key components of blood coagulation	157
5.2.11 Spectrofluorometric analysis shows the interaction of lunathrombase with thrombin/ fibrinogen/ FXa	161
5.2.12 Isothermal calorimetry analysis of the interaction between lunathrombase and thrombin /fibrinogen	163
5.2.13 Lunathrombase has <i>in vitro</i> thrombolytic potency	164
5.2.14 Lunathrombase is devoid of hemolytic activity and cytotoxicity against mammalian cells	165
5.2.15 Lunathrombase showed antiplatelet activity by inhibiting collagen/ADP/arachidonic acid-induced platelet aggregation	168
5.2.16 Lunathrombase increased cAMP level and inhibited COX-1 to exert its antiplatelet effect	170
5.2.17 Determination of <i>in vivo</i> toxicity of lunathrombase in Wister strain rats	173
5.2.17.1 Effect on haematological, serum biochemical and immunoglobulin parameters	173
5.2.17.2 Histopathological study	175
5.2.18 Lunathrombase demonstrated <i>in vivo</i> anticoagulant and defibrinogenating activity	176
5.3 Discussion	179
Bibliography	184
Chapter VI: Characterization and mechanism of anticoagulant action of β-sitosterol - a major component of the active anticoagulant fraction of <i>L. Indica</i> (AFLI)	191-216
6.1 Brief introduction	191
6.2 Results	191
6.2.1 BSS demonstrated dose-dependent anticoagulant activity of PPP and whole blood	191
6.2.2 BSS inhibited the catalytic activity of thrombin but did not influence FXa activity	194
6.2.3 BSS demonstrated antiplatelet activity and inhibited thrombin-induced platelet aggregation	198
6.2.4 The <i>in silico</i> binding study, spectrofluorometric analysis, and isothermal calorimetric titration suggest interaction of BSS with thrombin	199

Contents	Page No.
6.2.5 BSS demonstrated antithrombotic activity	203
6.2.6 BSS was devoid of hemolytic activity or cytotoxicity against mammalian cells	205
6.2.7 BSS demonstrated <i>in vivo</i> anticoagulant activity but was devoid of fibrinogenolytic activity	206
6.2.8 Antithrombotic effect of BSS in the carrageenan-induced mouse tail thrombosis model	208
6.3 Discussion	210
Bibliography	213
Chapter VII: The mechanism of anticoagulant action of an active anticoagulant fraction (AAF) from the fruits of <i>M. charantia</i>	217-245
7.1 Brief introduction	217
7.2 Results	217
7.2.1 Active anticoagulant fraction (AAF) demonstrated superior anticoagulant and fibrin(ogen)olytic activity, compared to the aqueous extract prepared from the whole fruits of <i>M. charantia</i>	217
7.2.2 SDS-PAGE analysis of fibrinogen/fibrin degradation by AAF	220
7.2.3 AAF did not inhibit thrombin or FXa in exerting its anticoagulant action	223
7.2.4 Fibrin(ogen)olytic activity of AAF was not influenced by endogenous protease inhibitors of plasma but inhibited by serine protease inhibitors	224
7.2.5 Spectrofluorometric analysis showed interaction of AAF with fibrinogen	225
7.2.6 AAF demonstrated antiplatelet activity and inhibited collagen and ADP-induced platelet aggregation	227
7.2.7 AAF demonstrated <i>in vitro</i> clot-bursting activity and an antithrombotic effect but no direct hemolytic activity or cytotoxicity against mammalian cells	228
7.2.8 Analysis of AAF	231
7.2.8.1 Phytochemical screening of AAF	231
7.2.8.2 Amino acid composition and LC-MS/MS analysis of the protein constituents of AAF	231
7.2.8.3 GC-MS analysis of AAF	235
7.2.9 AAF demonstrated post-storage activity	236
7.2.10 AAF demonstrated <i>in vivo</i> anticoagulant and defibrinogenating activity	236
7.2.11 Antithrombotic effect of AAF in the mice thrombus model	237
7.3 Discussion	239
Bibliography	242
Chapter VIII	246-247
Conclusion and future perspectives	
8.1 Conclusion	246
8.2 Future Perspectives	247
Publications	248-277
Addendum	278-299